tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Pancreatic Fistula D010185 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Rupture D012421 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Cheilitis D002613 2 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Earache D004433 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Impetigo D007169 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingivitis D005891 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Hemophilia B D002836 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Anus Diseases D001004 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schnitzler M Diabetes mellitus after kidney transplantation in the United States. 2003 Am. J. Transplant. pmid:14510709
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Frassetto LA et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. 2007 Am. J. Transplant. pmid:17949460
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Tang Q Pharmacokinetics of therapeutic Tregs. 2014 Am. J. Transplant. pmid:25358900
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
Sikma MA et al. Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. 2015 Am. J. Transplant. pmid:26053114
English RF et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. 2002 Am. J. Transplant. pmid:12243498
de Fontbrune FS et al. Veno-occlusive disease of the liver after lung transplantation. 2007 Am. J. Transplant. pmid:17697264
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Krenzien F et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. 2017 Am. J. Transplant. pmid:27754593
Gupta G et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. 2015 Am. J. Transplant. pmid:25988397
Ekberg H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. 2009 Am. J. Transplant. pmid:19563339
ter Meulen CG et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. 2004 Am. J. Transplant. pmid:15084178
Mehra MR et al. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. 2006 Am. J. Transplant. pmid:16686745
Grimm M et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. 2006 Am. J. Transplant. pmid:16686762
Sis B et al. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. 2006 Am. J. Transplant. pmid:16686769
Hernández-Fisac I et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. 2007 Am. J. Transplant. pmid:17725683
Damon C et al. Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. 2017 Am. J. Transplant. pmid:27597269
Bouamar R et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). 2013 Am. J. Transplant. pmid:23480233
Busque S et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. 2011 Am. J. Transplant. pmid:21943027
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Schwarz A et al. Polyoma virus nephropathy in native kidneys after lung transplantation. 2005 Am. J. Transplant. pmid:16162212
Flechner SM et al. Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. 2010 Am. J. Transplant. pmid:20883540
Benítez CE et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. 2010 Am. J. Transplant. pmid:20883560
Böger CA et al. Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. 2006 Am. J. Transplant. pmid:16889550
Shemesh E et al. The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. 2017 Am. J. Transplant. pmid:28321975
Tan HP et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. 2006 Am. J. Transplant. pmid:16889606
Lucey MR et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 2005 Am. J. Transplant. pmid:15816894
Pillebout E et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). 2005 Am. J. Transplant. pmid:15816895
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Van Laecke S et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 2009 Am. J. Transplant. pmid:19624560
Pescovitz MD et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. 2009 Am. J. Transplant. pmid:19663892
Mian AN et al. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. 2005 Am. J. Transplant. pmid:15636628
Gregoor PS and Weimar W Tacrolimus and pure red-cell aplasia. 2005 Am. J. Transplant. pmid:15636632
Bohl DL et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. 2005 Am. J. Transplant. pmid:16095500
Kasahara M et al. Living-donor liver transplantation for hepatoblastoma. 2005 Am. J. Transplant. pmid:16095502
Lemahieu WP et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. 2005 Am. J. Transplant. pmid:16095503
Gao R et al. Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. 2007 Am. J. Transplant. pmid:17391142
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Rodriguez-Rodriguez AE et al. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. 2013 Am. J. Transplant. pmid:23651473
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Neuberger JM et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. 2009 Am. J. Transplant. pmid:19120077
Momper JD et al. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. 2011 Am. J. Transplant. pmid:21714845
Tan HP et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. 2009 Am. J. Transplant. pmid:19120078
Ashman N et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. 2009 Am. J. Transplant. pmid:19120084
Lemahieu WP et al. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. 2004 Am. J. Transplant. pmid:15307840
Vongwiwatana A et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. 2004 Am. J. Transplant. pmid:14678043
Bressollette-Bodin C et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. 2005 Am. J. Transplant. pmid:15996241
Augustine JJ et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. 2005 Am. J. Transplant. pmid:15996247
Filler G et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. 2005 Am. J. Transplant. pmid:15996252
Fan DM et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. 2015 Am. J. Transplant. pmid:25808777
Awadalla Y et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. 2004 Am. J. Transplant. pmid:15367226
Luther P and Baldwin D Pioglitazone in the management of diabetes mellitus after transplantation. 2004 Am. J. Transplant. pmid:15575920
Dahm F et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. 2004 Am. J. Transplant. pmid:15575921
Pascher A et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. 2015 Am. J. Transplant. pmid:25677074
Okabayashi T et al. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. 2011 Am. J. Transplant. pmid:21883903
Hellemons ME et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. 2011 Am. J. Transplant. pmid:21883906
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Mulay AV et al. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. 2009 Am. J. Transplant. pmid:19353768
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Bourdeaux C et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. 2007 Am. J. Transplant. pmid:17173657
Mazariegos GV et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. 2005 Am. J. Transplant. pmid:15643991
Bahra M et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. 2005 Am. J. Transplant. pmid:15644002
Zheng H et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. 2003 Am. J. Transplant. pmid:12694072
Montgomery SP et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 2002 Am. J. Transplant. pmid:12118862
Ahsan N et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. 2002 Am. J. Transplant. pmid:12118902
Rostaing L et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23730730
van Hooff JP et al. Glucose metabolic disorder after transplantation. 2007 Am. J. Transplant. pmid:17511670
Heffron TG et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. 2007 Am. J. Transplant. pmid:17511684
Moench C et al. Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. 2007 Am. J. Transplant. pmid:17511685
Patlolla V et al. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. 2007 Am. J. Transplant. pmid:17564638
Tedesco-Silva H et al. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. 2015 Am. J. Transplant. pmid:25988935
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
McDonald RA et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. 2008 Am. J. Transplant. pmid:18416737
Triñanes J et al. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. 2017 Am. J. Transplant. pmid:28432716
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Posselt AM et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. 2010 Am. J. Transplant. pmid:20659093
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Teuteberg JJ et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. 2010 Am. J. Transplant. pmid:19889126
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444
Shapiro R et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. 2007 Am. J. Transplant. pmid:17908272
De Simone P et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 2012 Am. J. Transplant. pmid:22882750
Echeverri GJ et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. 2009 Am. J. Transplant. pmid:19775318
Gaston RS et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. 2009 Am. J. Transplant. pmid:19459794
Turgut F and Akcay A Renal function estimation in cirrhosis. 2009 Am. J. Transplant. pmid:19519814
Irish WD et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 2011 Am. J. Transplant. pmid:21564522
Tricot L et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. 2009 Am. J. Transplant. pmid:19519819
Friman S et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. 2011 Am. J. Transplant. pmid:21564523
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923
Brennan DC et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. 2005 Am. J. Transplant. pmid:15707414
Rogers J et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. 2003 Am. J. Transplant. pmid:14510702